Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
Items 101–200 of 562
Live attenuated pseudorabies virus developed using the CRISPR/Cas9 system
Tang, Y.-D., Liu, J.-T., Wang, T.-Y., An, T., Sun, M., Wang, S., Fang, Q., Hou, L., Tian, Z., & Cai, X. (2016) · Virus Research · doi:10.1016/j.virusres.2016.09.004 · Cited by 74
Epigenome Engineering in Cancer: Fairytale or a Realistic Path to the Clinic?
Falahi, F., Sgro, A., & Blancafort, P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00022 · Cited by 74
“Similarly, CRISPRs have also been exploited to disrupt viral genomes, including the integrated HIV provirus (98, 99) and the hepatitis B virus (HBV) genome both in vitro and in vivo (100).”
BackgroundMao, L., Ying, J., Sélekon, B., Gonofio, E., Wang, X., Nakouné, E. R., Wong, G., & Berthet, N. (2022) · Viruses · doi:10.3390/v14102112 · Cited by 70
Towards a new era in medicine: therapeutic genome editing
Porteus, M. H. (2015) · Genome Biology · doi:10.1186/s13059-015-0859-y · Cited by 69
Yin, C., Zhang, T., Li, F., Yang, F., Putatunda, R., Young, W., Khalili, K., Hu, W., & Zhang, Y. (2016) · AIDS · doi:10.1097/qad.0000000000001079 · Cited by 73
“Our finding was supported by several recent reports[31-33].”
ResultAnti‐HIV‐1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication
Ueda, S., Ebina, H., Kanemura, Y., Misawa, N., & Koyanagi, Y. (2016) · Microbiology and Immunology · doi:10.1111/1348-0421.12395 · Cited by 74
“gRNA expression plasmid DNA to target HIV-1 DNA was constructed as previously described (3).”
BackgroundMethodInfluentialSelf-citationHIV Diagnosis and Treatment through Advanced Technologies
Zulfiqar, H. F., Javed, A., Sumbal, S., Afroze, B., Ali, Q., Akbar, K., Nadeem, T., Rana, M. A., Nazar, Z. A., Nasir, I. A., et al. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00032 · Cited by 85
The CRISPR/Cas9 genome editing methodology as a weapon against human viruses.
White, M. K., Hu, W., & Khalili, K. (2015) · PubMed · Cited by 86
Exosomes in HIV infection: A review and critical look
Ellwanger, J. H., Veit, T. D., & Chies, J. A. B. (2017) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2017.05.021 · Cited by 71
Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections
Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Nahand, J. S., Piroozmand, A., Jajarmi, V., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112743 · Cited by 76
“cating latent HIV infection, targeting proviral DNA using CRISPR-Cas9 has been shown to prevent new HIV infection [66,111].”
Nuclease‐mediated genome editing: At the front‐line of functional genomics technology
Sakuma, T., & Woltjen, K. (2014) · Development Growth & Differentiation · doi:10.1111/dgd.12111 · Cited by 76
CRISPR-Cas9-Based Knockout of the Prion Protein and Its Effect on the Proteome
Mehrabian, M., Dylan, B., MacIsaac, S., Kim, J. K., Gunawardana, C. G., Wang, H., & Schmitt‐Ulms, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114594 · Cited by 76
“Following more than 10 years of work, during which the essential molecular components of clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 machinery were defined, numerous reports published in the past year documented how this adaptive immunity can be harnessed for genome editing in a wide range o…”
BackgroundInfluentialKennedy, E. M., & Cullen, B. R. (2015) · Virology · doi:10.1016/j.virol.2015.02.024 · Cited by 73
“and elsewhere, to the use of Spy-derived Cas9/sgRNA combinations, delivered by lentiviral vector transduction or transfection, to induce the mutational inactivation of the DNA genomes of HBV, HPV and HIV-1 (Ebina et al., 2013; Hu et al., 2014a; Hu et al., 2014b; Kennedy et al., 2015; Kennedy et al., 2014; Lin et al.,…”
InfluentialA CRISPR-Cas Cure for HIV/AIDS
Hussein, M., Molina, M. A., Berkhout, B., & Herrera-Carrillo, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021563 · Cited by 86
Tang, H., & Shrager, J. B. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506006 · Cited by 62
“More importantly, it makes it theoretically possible to repair genetic mutations in clinical diseases (Ebina et al, 2013; Sánchez-Rivera & Jacks, 2015).”
BackgroundCRISPR/Cas9: a double-edged sword when used to combat HIV infection
Chen, L., Wainberg, M. A., Das, A. T., & Berkhout, B. (2016) · Retrovirology · doi:10.1186/s12977-016-0270-0 · Cited by 67
Advances in Developing CAR T-Cell Therapy for HIV Cure
Qi, J., Ding, C., Jiang, X. L., & Gao, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00361 · Cited by 78
“The result showed efficient editing in target sites and great loss of LTR-driven expression (39).”
BackgroundEstablishment of a highly efficient virus-inducible CRISPR/Cas9 system in insect cells
Dong, Z., Chen, T., Zhang, J., Hu, N., Cao, M.-Y., Dong, F., Jiang, Y., Chen, P., Lu, C., & Pan, M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.03.009 · Cited by 65
Wang, J., Zhang, C., & Feng, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15039 · Cited by 63
CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge
Lee, C.-H. (2019) · Molecules · doi:10.3390/molecules24071349 · Cited by 66
“For screening of CRISPR/Cas9-mediated LTR activation, different versions of LTR-driven GFP or luciferase reporter systems were employed.”
BackgroundMethodResultInfluentialNegative Feedback Regulation of HIV-1 by Gene Editing Strategy
Kaminski, R., Chen, Y., Salkind, J., Bella, R., Young, W., Ferrante, P., Karn, J., Malcolm, T., Hu, W., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep31527 · Cited by 60
“CRISPR/Cas9 gene editing using a multiplex of different gRNAs that introduce InDel mutations as well as excision of segments of the viral DNA has also been utilized by several other laboratories 18,19 .”
Wigdahl, B. L. (2014) · MOJ Immunology · doi:10.15406/moji.2014.01.00022 · Cited by 71
“With respect to the use of this technology in the setting of HIV infection, several lines of research have been proposed including (i) disrupting HIV-1 entry coreceptors (CCR5, CXCR4) and proviral DNA-encoding viral proteins [13,22]; CCR5 gene targeting ZFNs are in phase II clinical trials for HIV/AIDS treatment [23],…”
MethodDelivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies
Ta, T. M., Malik, S., Anderson, E. M., Jones, A. D., Perchik, J., Freylikh, M., Sardo, L., Klase, Z. A., & Izumi, T. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.862270 · Cited by 62
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
Chou, T. C., Maggirwar, N. S., & Marsden, M. D. (2024) · Viruses · doi:10.3390/v16071163 · Cited by 86
“For example, CRISPR/Cas9 was used to genetically disrupt the HIV LTR, inhibiting active and latent provirus transcription [204].”
BackgroundMethodThe power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 70
“Therefore, Ebina firstly edited the LTR promotor by CRISPR/ Cas9 in 2013, causing the significant decrease of LTR-driven expression[67].”
Song, J., Zhang, X., Ge, Q., Yuan, C., Chu, L., Liang, H., Liao, Z., Liu, Q., Zhang, Z., & Zhang, B. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27050 · Cited by 59
“Recently, theCRISPR/Cas9 system has been successfully appliednot only for genomeediting in cells, but also for disrupting the genome of virus, including adenovirus, herpes simplex virus, and human immunodeficiency virus.(19,20) A number of experimental systems provide a clear proof that this approach has the potential…”
BackgroundCRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 63
Zhen, S., Lu, J., Liu, Y., Chen, W., & Li, X. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0131-9 · Cited by 56
Engineering T Cells to Functionally Cure HIV-1 Infection
Leibman, R. S., & Riley, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.70 · Cited by 60
Yang, H., & Chen, P. (2017) · Virus Research · doi:10.1016/j.virusres.2017.06.010 · Cited by 58
Gold Nanoparticle-Mediated Gene Therapy
Kanu, G. A., Parambath, J. B. M., Odeh, R. O. A., & Mohamed, A. A. M. (2022) · Cancers · doi:10.3390/cancers14215366 · Cited by 64
CRISPR/Cas9: a tool to eradicate HIV-1
Bhowmik, R., & Chaubey, B. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-022-00483-y · Cited by 72
“The study indicated the ability of CRISPR/Cas9 to effectively inhibit viral expression [21].”
BackgroundMethodUsing RNA as Molecular Code for Programming Cellular Function
Kushwaha, M., Rostain, W., Prakash, S., Duncan, J. N., & Jaramillo, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00297 · Cited by 61
CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy
Chen, S., Yu, X., & Guo, D. (2018) · Viruses · doi:10.3390/v10010040 · Cited by 57
“The latent provirus integrated in the genome of Jurkat cells, microglia cells, monocytic cells and HeLa cells can be removed by CRISPR/SpCas9 [73] [74] [75] .”
BackgroundEfficient viral delivery of Cas9 into human safe harbor
Hayashi, H., Kubo, Y., Izumida, M., & Matsuyama, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78450-8 · Cited by 64
Teng, M., Yao, Y., Nair, V., & Luo, J. (2021) · Viruses · doi:10.3390/v13050779 · Cited by 61
“Subsequently, the conserved site of the HIV-1 LTR U3 promoter region was chosen as a new gRNA target for CRISPR/Cas9- based therapeutic gene editing of integrated HIV genomes in microglial, promonocytic, and T cells, where the Cas9 nuclease was successful in the complete excision of the 9709-bp fragment of integrated…”
MethodInfluentialAbrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells
Cui, J., Techakriengkrai, N., Nedumpun, T., & Suradhat, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-66775-3 · Cited by 54
A High Excision Potential of TALENs for Integrated DNA of HIV-Based Lentiviral Vector
Ebina, H., Kanemura, Y., Misawa, N., Sakuma, T., Kobayashi, T., Yamamoto, T., & Koyanagi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120047 · Cited by 58
“To examine this, an LTIG-transduced Jurkat cell clone, c19 [26], which possesses one copy of the latent HIV provirus on chromosome 16, which can be induced after TNF-α stimulation, was transfected with TAR TALENs or T5 CRISPR plasmid DNA.”
BackgroundMethodInfluentialSelf-citationYuen, K., Wang, Z.-M., Wong, N.-H. M., Zhang, Z., Cheng, T.-F., Lui, W., Chan, C., & Jin, D. (2017) · Virus Research · doi:10.1016/j.virusres.2017.04.019 · Cited by 56
“, 2016) and multiple other viruses (Ebina et al., 2013; Bi et al., 2014; Hu et al., 2014; Dong et al., 2015; Kennedy et al., 2014, 2015; Lin et al., 2014; Seeger and Sohn, 2014; Liu et al., 2015; Zhen et al., 2015; van Diemen et al., 2016; Wang et al., 2016) were found to”
BackgroundCRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 62
HIV-1 functional cure: will the dream come true?
Liu, C., Ma, X., Liu, B., Chen, C., & Zhang, H. (2015) · BMC Medicine · doi:10.1186/s12916-015-0517-y · Cited by 54
Personalized therapeutic strategies for patients with retinitis pigmentosa
Zheng, A., Li, Y., & Tsang, S. H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1006192 · Cited by 59
“Recently, a multiplex approach targeting different enhancers and promoters within the long terminal repeats of HIV-1 was able to excise latent infection as well as sterilely vaccinate against new infection for myeloid cells in vitro [91,92].”
BackgroundKaur, K., Gupta, A., Rajput, A., & Kumar, M. (2016) · Scientific Reports · doi:10.1038/srep30870 · Cited by 54
CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection
Yin, L., Hu, S., Mei, S., Sun, H., Xu, F., Li, J., Zhu, W., Liu, X., Zhao, F., Zhang, D., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.018 · Cited by 52
“52,75 Furthermore, targeting the primer activation signal and the primer binding site also significantly inhibited HIV-1 replication (Fig.”
Nanotechnology approaches to eradicating HIV reservoirs
Cao, S., & Woodrow, K. A. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.002 · Cited by 56
Genetic correction using engineered nucleases for gene therapy applications
Lisa Li, H., Nakano, T., & Hotta, A. (2014) · Development, Growth & Differentiation · doi:10.1111/dgd.12107 · Cited by 48
“demonstrated disruption of the LTR region using CRISPR/gRNA in cultured cell lines (Ebina et al. 2013).”
BackgroundMethodLi, H., Sheng, C., Liu, H., Liu, G., Du, X., Du, J., Zhan, L., Li, P., Yang, C., Qi, L., et al. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16064 · Cited by 51
“The CRISPR/Cas9 system has been used to genome editing in many types of hosts, including human cells [15-17], several model organisms, and proviruses such as HIV [18, 19] and HPV [20], thus this system represents a potential means to radically cure chronic viral infection.”
MethodCRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
Lone, B. A., Karna, S. K. L., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2018) · Genetics Research International · doi:10.1155/2018/3797214 · Cited by 59
Genome editing strategies: potential tools for eradicating HIV-1/AIDS
Khalili, K., Kaminski, R., Gordon, J., Cosentino, L., & Hu, W. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-014-0308-9 · Cited by 53
“During the course of our investigation, two labs reported the successful editing of the HIV-1 LTR by ZFN and Cas9 targeting a single conserved transcription factor binding site (Ebina et al. 2013) or the HIV-1 trans-activation response (TAR) element (Qu et al.”
BackgroundMethodInfluentialA CRISPR method for genome engineering
Wilkinson, R. A., & Wiedenheft, B. (2014) · F1000Prime Reports · doi:10.12703/p6-3 · Cited by 53
“Here we provide a brief overview of CRISPR-mediated immunity and explain how the emerging new properties of this defense system are being repurposed for genome engineering in bacteria [6-9], yeast [10,11], human cells [10,12-28], insects [29-32], fish [33-37], worms [38-46], plants [47-54], frogs [55], pigs [56], and…”
BackgroundProgrammable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 51
“In addition to inactivation of proviral DNA and prevention of replication in infected cells, CRISPR-Cas9 can provide resistance against recurrent HIV infections and can target multiple spots inside the HIV genome.(234) The Cas9 protein of CRISPR-Cas9 can persist in human HSPCs.”
BackgroundVariability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 53
“In light of the benefits expected from the use of GETs, some cancer risk may become acceptable for lethal diseases such as Duchenne muscular dystrophy, for which the use of CRISPR/Cas9 may show promise 86 and numerous preclinical studies are ongoing 87 .”
InfluentialMeasuring the Success of HIV-1 Cure Strategies
Thomas, J., Ruggiero, A., Paxton, W. A., & Pollakis, G. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00134 · Cited by 54
“This approach may also be used to specifically knockout or attenuate the HIV1 provirus, for example, by targeting the LTR to disrupt viral gene expression or excise the integrated genome (Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016; Lebbink et al., 2017; Yin et al., 2017; Bella et al., 2018; Wang Q. et…”
MethodCRISPR/Cas9 and Nanotechnology Pertinence in Agricultural Crop Refinement
Naik, B. J., Shimoga, G. D., Kim, S.-C., Manjulatha, M., Palem, R. R., Palem, R. R., Kumar, M., Kim, S., & Lee, S. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.843575 · Cited by 52
Zhang, M., Li, H., & Jin, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1364742 · Cited by 73
“…plants (Seth and Harish, 2016; Soyk et al., 2017); eliminating pathogens by deleting their genes, such as the genomes of bacteria or viruses, in order to eliminate infectious diseases, offers hope for a complete cure for such diseases (Ebina et al., 2013; Yin et al., 2017; Ling et al., 2020).”
BackgroundStem cell-based therapies for HIV/AIDS
Pernet, O., Yadav, S. S., & An, D. S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.027 · Cited by 48
(2016) · doi:10.13918/j.issn.2095-8137.2016.4.191
“CRISPR/Cas9-based gene therapy offered a new tool to modify the targeted intervention points, such as CD4+ receptor and the CCR5 (Ebina et al., 2013; Li et al., 2015a).”
MethodApplications of CRISPR as a potential therapeutic
Luthra, R., Kaur, S. P., & Bhandari, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119908 · Cited by 55
CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
Baghini, S. S., Gardanova, Z. R., Abadi, S. A. H., Zaman, B. A., İlhan, A., Shomali, N., Adili, A., Moghaddar, R., & Yaseri, A. F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00336-6 · Cited by 53
“HIV-1 LTR Jurkat cells and HeLa cell line Plasmid Efficient cleavage of LTR target sites [278]”
BackgroundTimilsina, U., & Gaur, R. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000402 · Cited by 45
Elimination of infectious HIV DNA by CRISPR–Cas9
Das, A. T., Binda, C. S., & Berkhout, B. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.001 · Cited by 49
Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9
Oh, H. S., Neuhausser, W., Eggan, P., Angelova, M., Kirchner, R., Eggan, K. C., & Knipe, D. M. (2019) · eLife · doi:10.7554/elife.51662 · Cited by 45
“While some have reported editing of HIV proviruses (Ebina et al., 2013), latent EBV genomes (van Diemen et al.”
BackgroundCRISPR/Cas9: Regulations and challenges for law enforcement to combat its dual-use
Mir, T. U. G., Wani, A. K., Akhtar, N., & Shukla, S. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111274 · Cited by 55
Defective HIV-1 genomes and their potential impact on HIV pathogenesis
Kuniholm, J., Coote, C., & Henderson, A. J. (2022) · Retrovirology · doi:10.1186/s12977-022-00601-8 · Cited by 49
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy
Feelixge, H. S. D. S., Stone, D., Pietz, H. L., Roychoudhury, P., Greninger, A. L., Schiffer, J. T., Aubert, M., & Jerome, K. R. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.12.007 · Cited by 44
CRISPR-Mediated Epigenome Editing.
Enríquez, P. (2016) · PubMed Central · Cited by 61
Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS
Huang, Z., Tomitaka, A., Raymond, A., & Nair, M. (2017) · Gene Therapy · doi:10.1038/gt.2017.35 · Cited by 30
Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases
Ishida, K., Gee, P., & Hotta, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024751 · Cited by 40
Yamada, E., Nakaoka, S., Klein, L., Reith, E., Langer, S., Hopfensperger, K., Iwami, S., Schreiber, G., Kirchhoff, F., Koyanagi, Y., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.009 · Cited by 44
Self-citationThe Application of CRISPR/Cas Systems for Antiviral Therapy
Baddeley, H. J. E., & Isalan, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.745559 · Cited by 45
“After successful excision of the integrated HIV-1 provirus in human myeloid cells (Ebina et al., 2013; Hu et al., 2014), suppression of viral replication was achieved in ex vivo cultured CD4+ T-cells from infected patients (Kaminski et al., 2016b), with suppression of viral gene expression in HIV-1…”
MethodT-cell therapies for HIV: Preclinical successes and current clinical strategies
Patel, S., Jones, R. B., Nixon, D. F., & Bollard, C. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.04.007 · Cited by 40
“Several studies have employed the CRISPR system to knockdown HIV co-receptors CCR5 or CXCR4 on CD4+ T cells to provide resistance to viral infection [62–66].”
CRISPR /Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity
Mohammadzadeh, I., Qujeq, D., Yousefi, T., Ferns, G. A., Maniati, M., & Vaghari‐Tabari, M. (2020) · IUBMB Life · doi:10.1002/iub.2296 · Cited by 50
“This study demonstrated that a CRISPR/Cas9 system can cleave viral genome at LTR regions, induce mutation, and can even have the ability to eliminate internal integrated HIV genes from host cell genome.(26) This study showed that HIV latent infection can be treated with CRISPR/Cas9, paving the way for further studies.”
BackgroundEfficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System
Nguyen, H., Wilson, H., Jayakumar, S., Kulkarni, V., & Kulkarni, S. (2021) · Viruses · doi:10.3390/v13091850 · Cited by 44
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 45
Synthetic Biology for Therapeutic Applications
Abil, Z., Xiong, X., & Zhao, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500392q · Cited by 43
Applications of CRISPR-Cas9 mediated genome engineering
Yang, X. P. (2015) · Military Medical Research · doi:10.1186/s40779-015-0038-1 · Cited by 43
Damaging the Integrated HIV Proviral DNA with TALENs
Strong, C. L., Guerra, H. P., Mathew, K. R., Roy, N., Simpson, L. R., & Schiller, M. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125652 · Cited by 43
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9
Chou, Y., Krupp, A., Kaynor, C., Gaudin, R., Ma, M., Cahir-McFarland, E. D., & Kirchhausen, T. L. (2016) · Scientific Reports · doi:10.1038/srep36921 · Cited by 39
Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene
Gergen, J., Coulon, F., Crénéguy, A., Elain-Duret, N., Gutiérrez-Guerrero, A., Pinkenburg, O., Verhoeyen, E., Anegón, I., Nguyen, T. H., Halary, F. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192602 · Cited by 38
Sankaranantham, M. (2019) · Indian Journal of Sexually Transmitted Diseases and AIDS · doi:10.4103/ijstd.ijstd_112_15 · Cited by 37
“In theory, such gene‐edited stem cells could be introduced into HIV patients through bone marrow transplantation, the procedure used to transplant blood stem cells into leukemia patients, to give rise to HIV‐resistant immune systems.[14] Researchers engineered a molecule known as a chimeric antigen receptor (CAR) and…”
BackgroundThe Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses
Lin, H., Li, G., Peng, X., Deng, A., Ye, L., Shi, L., Wang, T., & He, J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.590989 · Cited by 49
“Here, Table 1 lists the research studies of HIV-1 infection via CRISPR/Cas9 techniques for editing the aforementioned gene sites (Cho et al., 2013; Ebina et al., 2013; Hu et al., 2014; Hou et al., 2015; TABLE 1 | Applications of CRISPR/Cas9 system for gene therapy of HIV infection.”
BackgroundMethodCRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 44
“…remove the proviral HIV-1 DNA from the host cell genome, and several research groups have reported the potential of the CRISPR-Cas9 system to disrupt latent HIV-1 provirus by targeting the long terminal repeat (LTR) region (Ebina et al, 2013; Hu et al, 2014; Zhu et al, 2015; Kaminski et al, 2016).”
BackgroundAntiviral Defenses in Plants through Genome Editing
Romay, G., & Bragard, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00047 · Cited by 41
The latest evidence for possible HIV-1 curative strategies
Pham, H. T., & Mésplède, T. (2018) · Drugs in Context · doi:10.7573/dic.212522 · Cited by 40
“Most recent works have been focused on some regions of the HIV-1 LTR that are highly conserved across HIV-1 clades [60,61,63,64].”
BackgroundHIV-1 Latency and Eradication: Past, Present and Future
Datta, P. K., Kaminski, R., Hu, W., Pirrone, V., Sullivan, N. T., Nonnemacher, M. R., Dampier, W., Wigdahl, B. L., & Khalili, K. (2016) · Current HIV Research · doi:10.2174/1570162x14666160324125536 · Cited by 40
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
Rajan, A., Shrivastava, S., Janhawi, Kumar, A., Singh, A. K., & Arora, P. K. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12135-2 · Cited by 37
“Furthermore, in vitro studies show that targeting highly conserved sequences of viral genome such as LTR sequences of HIV (Ebina et al. 2013; Liao et al. 2015), RdRP, and N gene of SARS-COV-2 and segment 6 and segment 4 of IAV decreased viral load in the cells (Abbott et al.”
BackgroundTang, Y.-D., Liu, J.-T., Fang, Q., Wang, T.-Y., Sun, M., An, T., Tian, Z., & Cai, X. (2016) · Viruses · doi:10.3390/v8040090 · Cited by 39
“The CRISPR/Cas9 system-derived from the bacterial adaptive immune system-has been used to successfully edit many viruses [18] [19] [20] [21] .”
MethodCRISPR/Cas9: Nature's gift to prokaryotes and an auspicious tool in genome editing
Manzoor, K. N., & Khan, A. A. (2019) · Journal of Basic Microbiology · doi:10.1002/jobm.201900420 · Cited by 43
“Viral genes were also shown to be deleted from the chromosome of the host cell [90].”
BackgroundGene Editing: A New Tool for Viral Disease
Kennedy, E. M., & Cullen, B. R. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-031129 · Cited by 38
Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants
Dampier, W., Sullivan, N. T., Chung, C.-H., Mell, J. C., Nonnemacher, M. R., & Wigdahl, B. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-12612-z · Cited by 33
“Each gRNA was scored using the following algorithm to: (1) find all sequences from the LANL which overlap the target region, requiring 10 bp flanks; (2) apply the scoring function across all gRNA-target pairs in the ungapped sequence; (3) report the highest score for each sequence and indicate whether there was an adj…”
MethodCRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA
Binda, C. S., Klaver, B., Berkhout, B., & Das, A. T. (2020) · Viruses · doi:10.3390/v12030330 · Cited by 36
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 36
Wang, Z., Wang, W., Cui, Y. C., Pan, Q., Zhu, W., Gendron, P., Guo, F., Cen, S., Witcher, M., & Liang, C. (2018) · Journal of Virology · doi:10.1128/jvi.01135-18 · Cited by 35
Editing CCR5: A Novel Approach to HIV Gene Therapy
Cornu, T. I., Mussolino, C., Bloom, K. M., & Cathomen, T. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_6 · Cited by 38
HIV-1 cure strategies: why CRISPR?
Atkins, A., Allen, A. G., Dampier, W., Haddad, E. K., Nonnemacher, M. R., & Wigdahl, B. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865302 · Cited by 33
CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases
Serajian, S., Ahmadpour, E., Oliveira, S. M. R., Pereira, M. D. L., & Heidarzadeh, S. (2021) · Pharmaceuticals · doi:10.3390/ph14111171 · Cited by 38
Zahedipour, F., Zahedipour, F., Zamani, P., Jaafari, M. R., & Sahebkar, A. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199314 · Cited by 38
Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas
Mefferd, A. L., Bogerd, H. P., Irwan, I. D., & Cullen, B. R. (2018) · Virology · doi:10.1016/j.virol.2018.05.016 · Cited by 33
“While there has been particular interest in using CRISPR/Cas as a means of cleaving and inactivating the latent HIV-1 proviruses found in a small number of resting memory T cells in patients on antiretroviral therapy with no detectable replicating HIV-1 (Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016; Liao…”
BackgroundViral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir
Roychoudhury, P., Feelixge, H. S. D. S., Reeves, D. B., Mayer, B. T., Stone, D., Schiffer, J. T., & Jerome, K. R. (2018) · BMC Biology · doi:10.1186/s12915-018-0544-1 · Cited by 37
“A number of recent studies have designed LTR-based CRISPR strategies and shown broad antiviral activity against HIV in a number of different model systems [7, 8, 12, 20, 21, 38, 44, 45].”
Background
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.